Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering Effective Care With BCMA Antibodies and Cellular Therapy

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Go online to PeerView.com/SJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Can you bet on BCMA for your patients with multiple myeloma (MM)? Based on their demonstrated ability to evade resistance to prior agents and induce deep and durable responses, BCMA CAR-T constructs and bispecific antibodies have emerged as core management options for patients with MM progressing on their therapeutic journey. In collaboration with the HealthTree Foundation for Multiple Myeloma, this expert oncology nurse–led activity uses case-based teaching examples to illustrate practical strategies for the delivery of care with BCMA therapeutics while highlighting strategies for patient education and safety management. Each presentation features resources and tools from the HealthTree Foundation for Multiple Myeloma designed to overcome some of the challenges patients face, increase awareness of BCMA-directed options, and foster collaboration between professionals and patients when faced with difficult-to-treat MM cases. Upon completion of this activity, participants should be better able to: Summarize current evidence and guidelines supporting the use of BCMA antibodies and CAR-T cell therapy across the spectrum of multiple myeloma; Implement team strategies to optimize the integration of anti-BCMA therapies, including in the context of a clinical trial, based on diagnostic evaluation, patient-related and disease-related factors, and prior treatment regimens; Provide education to patients on therapeutic expectations with BCMA therapy, delivery of care aspects, and the risk of treatment-emergent adverse events; and Develop team-based strategies to address practical aspects of care when using novel anti-BCMA therapies, including dosing and scheduling, care coordination, supportive care, and management of treatment-related toxicities, including ocular toxicity, CRS, and neurotoxicity, among others